Pfizer has voluntarily pulled its pulmonary arterial hypertension (PAH) drug Thelin (sitaxentan) from the markets in which it is approved - the EU, Canada and Australia - and is discontinuing ongoing clinical studies after three drug-related deaths occurred, due to liver toxicity.
Pfizer pulls PAH drug Thelin from market after unpredictable deaths
Pfizer has voluntarily pulled its pulmonary arterial hypertension (PAH) drug Thelin (sitaxentan) from the markets in which it is approved - the EU, Canada and Australia - and is discontinuing ongoing clinical studies after three drug-related deaths occurred, due to liver toxicity.
More from Cardiovascular
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Therapeutic Category
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.